The use of dedicated nitinol venous stents across the inguinal ligament shows “good outcomes” in terms of patency but reinterventions may be required, according to Prakash Saha, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK, who spoke about this topic at the American Venous Forum Annual Meeting (14–17 February, New Orleans, USA). The patency rates seen with these newer devices are comparable to data reported for the Wallstent (Boston Scientific).
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study published in the New England Journal of Medicine.
In a new study presented at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilisation rates of these potentially life-saving medications are low, particularly in the sub-group of pulmonary embolism patients who are critically ill.
The use of computerised clinical decision support systems among surgical patients are associated with a significant increase in the proportion of patients with adequately ordered treatment to prevent blood clots, and a significant decrease in the risk of developing a blood clot, according to a study published online by JAMA Surgery.
CorVascular has entered into a distribution agreement with Novarix. The IV-eye, developed and manufactured in the UK by Novarix, is a near infrared (NIR) vein imaging device designed to aid healthcare professionals in finding suitable peripheral veins for both cannulation and venipuncture.
Following Health Canada regulatory approval, BTG is to launch its polidocanol injectable foam (Varithena), a drug/device combination product used to treat varicose veins, in Canada. The product is intended for use in adults with clinically significant venous reflux as diagnosed by duplex ultrasound.
Philips has announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market.
Some research data suggest there could be a synergistic effect between immunotherapy and minimally invasive procedures. Tumour types that do not respond to checkpoint inhibitors – so called “cold tumours” – could “turn hot” after treatment with locoregional therapies, writes Melanie Lee, London, UK.
BTG has announced a collaboration with the Society of Interventional Oncology (SIO; a global organisation working to nurture and support interventional oncology worldwide) to explore the role of interventional oncology alongside immuno-oncology.
Medtronic has announced that the US FDA has cleared an expanded indication for the OsteoCool radiofrequency (RF) ablation system.
The Karolinska Institute-sponsored, prospective, observational MAVERRIC study aims to demonstrate that a strategy of first line local microwave ablation of colorectal liver metastases is not inferior to liver resection in terms of survival rates at three years.
Sirtex has announced that the SARAH (Sorafenib vs. radioembolisation in advanced hepatocellular carcinoma) randomised controlled study results will be presented at the upcoming European Association for the Study of the Liver (EASL), International Liver Congress (ILC) in Amsterdam, the Netherlands (19–23 April 2017).
WCIO has announced via email communication that the board of directors of the organisation, a non-profit association that supports and promotes the field of interventional oncology (IO), has established the Society of Interventional Oncology (SIO), effective 17 January. The society’s annual IO conference will maintain its name of WCIO.
A study, published in the Journal of Vascular and Interventional Radiology suggests that percutaneous image-guided irreversible electroporation of unresectable locally advanced pancreatic adenocarcinoma is associated with a satisfactory safety profile.
Guerbet has announced that the Thailand FDA has given approval of a new indication for Lipiodol Ultra-Fluide for selective hepatic intra-arterial injection for visualisation, localisation and vectorisation during transarterial chemoembolization of tumours in adults with known, intermediate stage hepatocellular carcinoma.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos